Foundayo cut sleep apnea events by 44% without PAP. Can Lilly turn an obesity pill into its next OSA franchise?
Foundayo cut sleep apnea events by up to 44% in Phase 3 ATTAIN-OSA, giving Eli Lilly another potential obesity-linked OSA treatment.
Pharma & Biotech
Features & Analysis
Can branded GLP-1 medicines replace compounded weight-loss drugs in Hims & Hers growth strategy?
Lilly is bringing Zepbound and Foundayo to Hims & Hers, turning a former GLP-1 disruptor into a branded obesity-drug distribution channel.
Pharma & Biotech
Eli Lilly brings Zepbound and Foundayo to Hims & Hers, but who gains most from the deal?
Eli Lilly and Hims & Hers expand access to Zepbound and Foundayo from $149 monthly. Discover the impact on obesity medicine distribution.
Pharma & Biotech
Eli Lilly just lifted its 2026 sales outlook by $5.5bn, but can surging GLP-1 demand keep outrunning price pressure?
Eli Lilly raises 2026 revenue guidance to $91bn–$92bn as Mounjaro and Zepbound sales surge. Explore its earnings, pipeline and risks.
Pharma & Biotech
Eli Lilly puts retatrutide, Foundayo and eloraTZP on one stage as obesity pipeline widens
Eli Lilly will use the European Association for the Study of Diabetes 2026 meeting to detail Phase 3 retatrutide results, new Foundayo data and the first Phase 2 readout for eloraTZP, revealing how the company intends to segment an increasingly competitive obesity and diabetes market.
Features & Analysis
Why small-molecule GLP-1 pills could matter even if injectable obesity drugs remain more powerful
Foundayo became the first approved nonpeptide small-molecule GLP-1 obesity drug in 2026, replacing injectable peptide chemistry with a tablet that can be taken without food or water restrictions.
Features & Analysis
Some patients may now receive real retatrutide before FDA approval. Most people discussing it online still will not qualify
Eli Lilly and Company has created a limited expanded-access pathway for adults with severe, treatment-resistant obesity, even as regulators warn that products sold online as retatrutide are unapproved, potentially contaminated and illegal to compound.
Pharma & Biotech
Evidation GLP-1 study reveals major growth runway but exposes widening access gaps
Discover how Evidation’s 165,000-person study reveals GLP-1 growth potential, access gaps and persistence risks shaping obesity care. Read more.
Pharma & Biotech
Can Eli Lilly’s Foundayo and retatrutide deepen its grip on the diabetes and obesity market?
Find out how Eli Lilly’s Foundayo and retatrutide data could reshape diabetes, obesity and cardiometabolic care.
Pharma & Biotech
Could Eli Lilly’s $4.5bn Indiana investment widen its lead in obesity and advanced therapies?
Obesity drug demand is outrunning pharma capacity. Eli Lilly’s Indiana bet shows manufacturing is now a strategic moat.